Phenotype
|
Fish
|
Conditions
|
Figures
|
whole organism ddit4 expression amount, ameliorated
|
nr3c1ia30/ia30
|
chemical treatment by environment: dexamethasone
|
Figure 5
from Dinarello et al., 2022
|
whole organism epas1a expression amount, ameliorated
|
nr3c1ia30/ia30
|
chemical treatment by environment: dexamethasone
|
Figure 1
from Dinarello et al., 2022
|
whole organism hif1al expression amount, ameliorated
|
nr3c1ia30/ia30
|
chemical treatment by environment: dexamethasone
|
Figure 5
from Dinarello et al., 2022
|
whole organism cortisol increased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 4
from Facchinello et al., 2017
|
whole organism ucp3 expression decreased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Figure 3
from Dinarello et al., 2022
|
whole organism crhb expression increased amount, abnormal
|
nr3c1ia30/ia30
|
mechanical stress
|
Fig. 4
from Facchinello et al., 2017
|
whole organism ulk2 expression amount, ameliorated
|
nr3c1ia30/ia30
|
chemical treatment by environment: dexamethasone
|
Figure 5
from Dinarello et al., 2022
|
whole organism nr3c2 expression increased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Figure 2
from Dinarello et al., 2022
|
whole organism ucp3 expression amount, ameliorated
|
nr3c1ia30/ia30
|
chemical treatment by environment: dexamethasone
|
Figure 3
from Dinarello et al., 2022
|
whole organism pomca expression increased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 4
from Facchinello et al., 2017
|
trabecular layer of ventricle decreased object quality, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 2
from Facchinello et al., 2017
|
whole organism hsd11b2 expression decreased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 5
from Facchinello et al., 2017
|
whole organism slc25a25a expression amount, ameliorated
|
nr3c1ia30/ia30
|
chemical treatment by environment: dexamethasone
|
Figure 3
from Dinarello et al., 2022
|
whole organism crhb expression increased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 4
from Facchinello et al., 2017
|
whole organism epas1a expression increased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Figure 1
from Dinarello et al., 2022
|
whole organism socs3a expression amount, ameliorated
|
nr3c1ia30/ia30
|
chemical treatment by environment: dexamethasone
|
Figure 5
from Dinarello et al., 2022
|
heart structure, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 2
from Facchinello et al., 2017
|
whole organism klf9 expression amount, ameliorated
|
nr3c1ia30/ia30
|
chemical treatment by environment: dexamethasone
|
Figure 1
from Dinarello et al., 2022
|
whole organism pomca expression increased amount, abnormal
|
nr3c1ia30/ia30
|
mechanical stress
|
Fig. 4
from Facchinello et al., 2017
|
whole organism nr3c1 expression decreased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Figure 1
from Dinarello et al., 2022
Fig. S1
from Facchinello et al., 2017
|
intestinal bulb epithelium decreased thickness, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 2
from Facchinello et al., 2017
|
whole organism viability, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 1
from Facchinello et al., 2017
|
whole organism star expression increased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 5
from Facchinello et al., 2017
|
whole organism fkbp5 expression decreased amount, abnormal
|
nr3c1ia30/ia30
|
mechanical stress
|
Fig. 4
from Facchinello et al., 2017
|
whole organism fkbp5 expression decreased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 4
from Facchinello et al., 2017
|
whole organism cortisol increased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 4
from Facchinello et al., 2017
|
whole organism ucp2 expression amount, ameliorated
|
nr3c1ia30/ia30
|
chemical treatment by environment: dexamethasone
|
Figure 1
from Dinarello et al., 2022
|
subcutaneous fat increased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 2
from Facchinello et al., 2017
|
whole organism ucp2 expression decreased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Figure 1
from Dinarello et al., 2022
|
pancreas decreased size, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Fig. 2
from Facchinello et al., 2017
|
whole organism cortisol increased amount, abnormal
|
nr3c1ia30/ia30
|
mechanical stress
|
Fig. 4
from Facchinello et al., 2017
|
whole organism slc25a25a expression decreased amount, abnormal
|
nr3c1ia30/ia30
|
standard conditions
|
Figure 3
from Dinarello et al., 2022
|
whole organism cortisol increased amount, abnormal
|
nr3c1ia30/ia30
|
mechanical stress
|
Fig. 4
from Facchinello et al., 2017
|
whole organism EGFP expression decreased amount, abnormal
|
nr3c1ia30/ia30; ia20Tg
|
chemical treatment: dexamethasone
|
Fig. 3
from Facchinello et al., 2017
|
whole organism EGFP expression decreased amount, abnormal
|
nr3c1ia30/ia30; ia20Tg
|
chemical treatment: dexamethasone
|
Fig. 3
from Facchinello et al., 2017
|
whole organism fkbp5 expression decreased amount, abnormal
|
nr3c1ia30/ia30; ia20Tg
|
chemical treatment: dexamethasone
|
Fig. 3
from Facchinello et al., 2017
|
whole organism foxo3b expression decreased amount, abnormal
|
nr3c1ia30/ia30; ia20Tg
|
chemical treatment: dexamethasone
|
Fig. 3
from Facchinello et al., 2017
|
whole organism foxo3b expression decreased amount, abnormal
|
nr3c1ia30/ia30; ia20Tg
|
control
|
Fig. 3
from Facchinello et al., 2017
|
whole organism fkbp5 expression decreased amount, abnormal
|
nr3c1ia30/ia30; ia20Tg
|
control
|
Fig. 3
from Facchinello et al., 2017
|
whole organism EGFP expression decreased amount, abnormal
|
nr3c1ia30/ia30; ia20Tg
|
control
|
Fig. 3
from Facchinello et al., 2017
|
whole organism EGFP expression decreased amount, abnormal
|
nr3c1ia30/ia30; ia20Tg
|
control
|
Fig. 3
from Facchinello et al., 2017
|
whole organism EGFP expression amount, ameliorated
|
nr3c1ia30/ia30; ia21Tg
|
chemical treatment: dexamethasone
|
Fig. S3
from Vettori et al., 2017
|
intestine EGFP expression decreased amount, abnormal
|
nr3c1ia30/ia30; ia28Tg
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
yolk present, abnormal
|
nr3c1ia30/+; stat3ia23/+
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
head decreased size, abnormal
|
nr3c1ia30/+; stat3ia23/+
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
whole organism viability, abnormal
|
nr3c1ia30/+; stat3ia23/+
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
pericardium edematous, abnormal
|
nr3c1ia30/+; stat3ia23/+
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
yolk present, abnormal
|
nr3c1ia30/+; stat3ia23/ia23
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
head decreased size, abnormal
|
nr3c1ia30/+; stat3ia23/ia23
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
whole organism viability, abnormal
|
nr3c1ia30/+; stat3ia23/ia23
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
pericardium edematous, abnormal
|
nr3c1ia30/+; stat3ia23/ia23
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
yolk present, abnormal
|
nr3c1ia30/ia30; stat3ia23/+
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
head decreased size, abnormal
|
nr3c1ia30/ia30; stat3ia23/+
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
whole organism viability, abnormal
|
nr3c1ia30/ia30; stat3ia23/+
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
pericardium edematous, abnormal
|
nr3c1ia30/ia30; stat3ia23/+
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
yolk present, abnormal
|
nr3c1ia30/ia30; stat3ia23/ia23
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
head decreased size, abnormal
|
nr3c1ia30/ia30; stat3ia23/ia23
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
whole organism viability, abnormal
|
nr3c1ia30/ia30; stat3ia23/ia23
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|
pericardium edematous, abnormal
|
nr3c1ia30/ia30; stat3ia23/ia23
|
standard conditions
|
Figure 4
from Dinarello et al., 2022
|